Abstract-We examined the effect of thromboxane A2 (TXA2) synthetase inhibitor, OKY-046, on bronchoconstriction induced by antigen and various spasmogenic mediators in guinea pigs in vivo. Further, inhibitory activities of OKY-046 on contractions of isolated tracheae and lung parenchymal strips induced by various contractile agents were also investigated in vitro. OKY-046, but not indomethacin, significantly inhibited antigen-induced bronchoconstriction in a dose-dependent manner. Moreover, OKY-046 attenuated bronchoconstrictions induced by peptide leukotrienes (LTs) and platelet activating factor (PAF), but not those by histamine, prostaglandin D2 (PGD2) and STA2 (a stable TXA2 mimetic agent). Although contractile responses induced by spasmogens such as peptide LTs, PAF and hista mine were not influenced by OKY-046 in isolated tracheae, OKY-046 elicited significant and concentration-dependent inhibitions against contractile responses induced by peptide LTs and PAF in isolated lung parenchymal strips. These results suggest the possible involvement of TXA2 in the development of anaphylactic bronchoconstriction in sensitized guinea pigs.
The release of eicosanoids from lung tissues in response to immunological stimuli has been described previously (1, 2) . Among eicosa noids, thromboxane A2 (TXA2), which is produced by platelets, mononuclear leu kocytes, lung mast cells and other cells, has been considered as one of the important mediators (3-7) in inflammatory respiratory diseases such as asthma, since it has potent contractile activities on pulmonary airways and blood vessels (4, 8) beside promoting platelet aggregation. However, the activity of TAX2 on airway function in vivo has been difficult to assess due to the short half-life of this mediator in blood (9).
In the present study, we examined the role of TXA2 in anaphylactic bronchoconstriction by using a potent and selective TXA2 syn thetase inhibitor, (E)-3-[p-(1 H-imidazol-1 ylmethyl) phenyl]-2-propenoic acid (OKY 046) (10), in the guinea pig. Furthermore, in hibitory activities of OKY-046 on broncho constriction responses induced by various spasmogenic mediators such as histamine, peptide leukotrienes (LTs) and platelet ac tivating factor (PAF) were also investigated both in vivo and in vitro.
Materials and Methods

Animals
Male Hartley guinea pigs weighing 250 to 500 g were used throughout the experiments. Drug
Either the sodium or hydrochloride salt of OKY-046 was used. Leukotriene (LT) C4, LTD4, LTE4, PGD2, 9,11-epithio-11,12 methano-TXA2 (STA2, a stable TXA2 mimetic agonist) and platelet activating factor (PAF) were synthesized by Ono. LTC4, LTD4 and LTE4 (dissolved in 50% ethanol) and PGD2 Preparation of guinea pig tracheal and lung parenchymal strips: The animals were sacri ficed by a sharp blow to the head, exan guinated, and the tracheae and lungs were isolated. Tracheae were carefully trimmed of excess fatty and connective tissues and cut into zigzag strips of equal number of seg ments. The lung parenchymal strips were removed from the outer edge of the right and left lower lobes of the lung. Each preparation was suspended under 0.5 g of passive tension in a 10-ml organ bath containing Krebs Henseleit solution, which was maintained at 37°C, pH 7.4, and continuously aerated with 95% 02-5% C02. Contractions of these tissues were measured by using an isotonic trans ducer (Nihon Kohden, TD112S) for the tracheal strip and a force-displacement trans ducer (Nihon Kohden, TB611T) for the lung parenchymal strip. After each tissue was equilibrated for 0.5 to 1 hr before commence ment of the experiment, constant responses to carbachol (10-6 M) for tracheal strips and acetylcholine (10-5 M) for lung parenchymal strips were obtained at least twice. Effect of spasmogen-induced contractile re sponses After a maximally effective concentration of carbachol (10-5 M) for tracheal strips or acetylcholine (10-3 M) for parenchymal strips was obtained, cumulative concen tration-response curves for , contractile agonists, i.e., histamine, LTC4, LTD4, STA2 and PG D2, were constructed by successive increases in the bath concentration of these agonists. In the case of PAF, all strips obtained from the same animal were challenged with only one concentration of this agonist be cause of its tachyphylactic effect (12). To minimize the variation between tissues of animals, contractile responses were ex pressed as a percentage of the maximal re sponse with carbachol (10-5 M) or acetyl choline (10-3 M). Statistical evaluation Statistical evaluations were made by Student's unpaired or paired t-test, with a probability value of P<0.05 regarded as significant.
Results
In vivo
Inhibitory activities on antigen-induced bronchoconstrictions:
Administration of an tigen in sensitized guinea pigs produced a bronchoconstriction with rapid onset (within 30 sec) and long-lasting action (more than 15 min) characterized by large increases in insufflation pressure (77.3±4.8% of max imal increase at 4 min) and a temporal but an abrupt hypertension (34.4±8.4 mmHg at 2 min) followed by slight hypotension (-6.3± 2.2 mmHg at 15 min). The peak in broncho constriction and hypertension occurred ap proximately 2 to 5 min and 1 to 3 min after antigen challenge, respectively. OKY-046 significantly inhibited both bronchoconstric tion and hypertension induced by antigen in a dose-dependent manner at doses ranging *, ** and *** indicate sig nificant differences compared with the control where P<0.05, P<0.01 and P<0.001, respective!y. from 1 to 10 mg/kg. On the other hand, indomethacin significantly inhibited this air way response only within 1 min after chal lenge, although it almost prevented the pressor response (Fig. 1 ) .
Inhibitory activities on responses induced by various spasmogens:
OKY-046, when given as a single bolus i.v.-injection, had no inhibitory effects on histamine (10 /cg/kg, i.v.)-, PGD2 (100 iig/kg, i.v.) and STA2 (3 fig/kg, kg ) produced a biphasic bronchoconstriction with peaks that appeared at 30-60 sec and 3-4 min, and elicited a transient hypertensive effect followed by hypotension 2 to 4 min after administration (Fig. 2) . OKY-046 pre ferentially inhibited the initial phase at doses ranging from 0.1 to 1 mg/kg, but had no in fluence on the latter phase of bronchocon striction. Indomethacin also inhibited the air Significant difference compared to the control was determined using Student's paired t-test for histamine and STA2 or the unpaired t-test for PGD2. (Fig. 4) . Intravenous administration of PAF (0.3 itg/kg) elicited temporal bronchoconstric tions with rapid onset (within 30 sec). An increase in insufflation pressure of 61.9± 7.9% was accompanied by a transient in crease followed by a sustained fall (3 to 10 min) in blood pressure. OKY-046 showed a dose-dependent attenuation against broncho constriction and hypertension at doses rang ing from 1 to 10 mg/kg. Indomethacin also significantly attenuated the spasmogenic and hypertensive activities of PAF (Fig. 5) .
I n vitro
In isolated tracheal strips, OKY-046 (10-4 M) did not show any inhibitory activities against contractile responses induced by histamine, PGD2, STA2, LTC4 and LTD4 (Table 2) .
In isolated lung parenchymal strips, OKY 046 (10-4 M) similarly did not show any in hibitory effects on the contractile responses induced by histamine, PGD2 and STA2 (Table  2) . However, O KY-046 (10-5-10-4 M) pro duced significant and concentration -de pendent inhibitions on LTD4-induced con tractions and shifted the concentration response curve towards the right in lung parenchymal strips (Fig. 6) . Indomethacin also showed significant inhibitions on LTD4 induced contractions in lung parenchymal strips (Fig. 6) . OKY-046 or indomethacin in hibited PAF-induced contraction in a con centration-dependent manner (Fig. 7) .
Discussion
We investigated the effect of OKY-046 on experimental asthma in sensitized guinea pigs. The present study confirmed that OKY 046, but not indomethacin, elicited a dose dependent inhibitory effect on antigen *, **, and *** indicate significant differences in comparison with the control where P<0.05, P<0.01 and P<0.001, respectively. In our in vitro studies, OKY-046 showed no effect on the contractile responses induced by histamine, STA2 and PGD2 in both tracheae and lung parenchymal strips. The findings suggest that such spasmongen-induced air way tissue contractions are not mediated via the actions of TXA2, and OKY-046 has no direct antagonism against the actions of these spasmogens. LTD4-induced contractions of lung paren chymal strips were significantly attenuated by either OKY-046 or indomethacin. Weichman et al. (13) reported that peptide LTs-induced contractions may be mediated in part by con tractile cyclooxygenase metabolites in lung parenchymal strips. Furthermore, evidences that TXA2 is released from lung parenchyma when stimulated with peptide LTs have been documented (13, 14) . Therefore, the present in vitro studies suggest that TXA2 is a strong candidate for the contractile cyclooxygenase metabolite in mediating peptide LTs-induced contractions of lung parenchymal strips. How ever, the origin of TXA2 in lung parenchyma is unclear, although TXA2 is produced by platelets, mononuclear leukocytes, mast cells and other cells (3) (4) (5) (6) (7) . On the other hand, OKY-046 did not show any inhibitory effects on the contractile responses induced by LTC4 or LTD4 in guinea pig tracheae. This suggests that the involvement of TXA2 on peptide LTs-induced tracheal contractions can be discounted. Although guinea pig trachea is capable of synthesizing TXA2, the major cyclooxygenase product produced by this tissue is PGE2 (15). On the other hand, Ally et al. (16) demonstrated that guinea pig lung parenchyma synthesizes predominantly TXA2. Therefore, it is conceivable that dif ferent effects of OKY-046 on trachea and lung parenchyma may be due to the difference in the amounts of TXA2 produced by peptide LTs in these two tissues.
It has been shown that peptide LTs are released from sensitized guinea pig lung fragment stimulated with antigen (17) and have potent contractile activities on airway tissues in vivo and in vitro (18) (19) (20) (21) . Also Andersson (22) reported that peptide LTs are involved in anaphylactic bronchocon striction using a specific LT antagonist FPL 55712. In the present in vivo study, we showed that OKY-046 attenuated transient bronchoconstriction and hypertension in duced by peptide LTs. OKY-046 showed no inhibitory effect on LTD4-induced bron choconstriction with indomethacin treatment, and elicited significant inhibition on con tractile responses induced by LTD4 in lung parenchymal but not tracheal strips. Further more, evidences to indicate peptide LTs can release TXA2 from guinea pig lung paren chymal strips (14) and perfused lung (23) have been documented. Therefore, it is conceivable that the inhibitory effect of OKY 046 on LTs-induced bronchoconstriction is attributable to inhibition of TXA2 generation in peripheral airways. An attenuation of the initial phase of bronchoconstriction by indo methacin (similar to OKY-046) is probably due to suppression of TXA2 production in peripheral airways.
PAF is released from perfused guinea pig lungs in response to antigen (24) . Further more, Lagente et al. (25) demonstrated that Ro 19-3704, a PAF antagonist. inhibits ana phylactic bronchoconstriction. These evi dences suggest the possible involvement of PAF in antigen-induced bronchoconstriction. We confirmed the potent spasmogenic ac tivity of PAF (Fig. 5) . Although PAF-induced bronchoconstriction was inhibited by OKY 046 and indomethacin, it seems unlikely that the inhibitory effects of these two compounds were attributed to direct antagonisms against PAF since the hypotensive responses induced by i.v. administration of PAF were not affected by these two compounds. PAF induces platelet-dependent bronchoconstriction (26) and stimulates the release of TXA2 from guinea pig lung tissue (27). Furthermore, PAF causes platelet aggregation, platelet and neutrophil diapedesis immediately after its systemic administration in guinea pigs (25, 28) . Therefore, it is possible that the inhibitory effects of OKY-046 and indomethacin against PAF-induced bronchoconstrictions are at tributable to the inhibition of PAF-induced TXA2 generation through platelet aggregation.
OKY-046 attenuated the pressor response induced by peptide LTs, PAF and antigen in accordance with the inhibitory activity on the airway response. In addition, Katsura et al. (29) reported that STA2 caused both bron choconstriction and the pressor response. Therefore, TXA2 is most likely to be involved in peptide LTs-, PAF and antigen-induced responses if assessed by responses of the blood pressure.
Histamine is considered as a potent me diator in bronchoconstriction following an tigen challenges in guinea pigs (30, 31). OKY 046 had no inhibitory effects against the con tractile responses induced by exogenous his tamine. Accordingly, it is unlikely that the anti asthmatic effect of OKY-046 is due to an tagonism on the contractile action of hista mine.
Indomethacin did not elicit any effect on antigen-induced bronchoconstriction except 1 min after antigen challenge (Fig. 1) (9), and/or causes the shunt of arachi donic acid to the 5-lipoxygenase pathway (36) .
In conclusion, we demonstrated that OKY 046 inhibited antigen-induced anaphylactic bronchoconstrictions in sensitized guinea pigs in vivo. The inhibitory effect of OKY-046 is probably due to the inhibition of TXA2 pro duction directly from an antigen-antibody re action and/or indirectly via peptide LTs or PAF in the peripheral airways.
